What is the clinical evidence from this study?

Study design: Other. Population: MI-induced chronic heart failure (n=70). Intervention: GLP-1 or AC3174 vs. Vehicle. Primary outcome: Left ventricular ejection fraction (LVEF) at end of study (p=<0.05).

November 16, 2010Cardiovascular DiabetologyOpen Access

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

Q: What are the key findings of this study?

Chronic treatment with GLP-1 or the exenatide analogue AC3174 significantly improved left ventricular ejection fraction and survival compared to vehicle in rats with MI-induced chronic heart failure.

View Full Paper

Ask AI

Bookmark

Key result

Chronic treatment with GLP-1 or the exenatide analogue AC3174 significantly improved left ventricular ejection fraction and survival compared to vehicle in rats with MI-induced chronic heart failure.

Why the study?

Does GLP-1 or AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure?

Population

69 male Sprague-Dawley rats with myocardial infarction-induced chronic heart failure and sham-operated…

Comparison

Glucagon-like peptide-1 at 2.5 or 25… vs Vehicle via subcutaneous infusion for 11 weeks

Design

Preclinical, randomly assigned to treatment groups, Images were digitally…

Follow-up

11 weeks

Authors

QLQue LiuNanjing University of Chinese Medicine CAChristen M. AndersonUniversity of North Carolina at Chapel Hill ABAnatoly Broyde

Discussion

Member takes

Implication

Hypothesis-generating in rat post-MI HF; human trials required before clinical consideration.

Structured PICO

Does GLP-1 or AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure?

Population

70 male Sprague-Dawley rats with MI-induced chronic heart failure and LV infarct size between 20% and 45%, followed for 11 weeks of treatment.

Intervention

Glucagon-like peptide-1 (GLP-1) at 2.5 or 25 pmol/kg/min, or exenatide analog AC3174 at 1.7 or 5 pmol/kg/min, via subcutaneous infusion for 11 weeks

Comparator

Vehicle (25% DMSO + 75% H2O) via subcutaneous infusion for 11 weeks

Outcome

Cardiac function (LVEF, end diastolic pressure), cardiac remodeling, insulin sensitivity, and exercise capacity at 11 weekssurrogate

Main Result

Absolute Event Rate: 43% vs 31%

p-value: p=<0.05

Chronic treatment with GLP-1 or the exenatide analog AC3174 improves cardiac function, remodeling, insulin sensitivity, and survival in a rat model of chronic heart failure.

Limitations

Standard treatments for MI, such as ACE-inhibitors, were not co-administered with GLP-1 or AC3174.
Levels of catecholamines, cortisol, glucagon, free fatty acids, renin, and aldosterone were not measured in the MI rat model.

Cite This Study

Liu et al. (2010) studied MI-induced chronic heart failure (n=70). GLP-1 or AC3174 vs. Vehicle was evaluated on Left ventricular ejection fraction (LVEF) at end of study (p=<0.05). Chronic treatment with GLP-1 or the exenatide analogue AC3174 significantly improved left ventricular ejection fraction and survival compared to vehicle in rats with MI-induced chronic heart failure.

synapsesocial.com/papers/6a20f62010699ec7be2ac898 https://doi.org/10.1186/1475-2840-9-76

Topics

HFrEF treatment Heart failure SGLT2 inhibitors in heart failure

View Full Paper

Ask AI

Bookmark

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Topics

Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Topics

Also Consider